(60 days)
Not Found
No
The summary describes a physical device for temperature regulation and gastric decompression, with no mention of AI or ML technologies in its function or description.
No.
The device's description and intended use focus on regulating patient temperature and providing gastric decompression, which are therapeutic functions. However, the document provided is a premarket submission for an FDA-regulated device, and the question is whether the device is a therapeutic device, not whether it has therapeutic functions. Generally, a therapeutic device is regulated as a medical device for therapeutic purposes within the FDA framework. While the device clearly serves therapeutic purposes, the core function of the device itself, as described by the question, is not inherently therapeutic. Instead, it is connected to a "Hyper/Hypothermia System," which seems to be the therapeutic part.
No
The device is described as a "thermal regulating device" that controls patient temperature and provides gastric decompression and suctioning. Its purpose is therapeutic (temperature modulation, gastric decompression) rather than diagnostic (identifying or characterizing a disease or condition).
No
The device description clearly describes a physical, multi-lumen silicone tube and its connection to external hardware (heat exchangers and wall suction). There is no mention of software as the primary or sole component.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states that the device is for thermal regulating and gastric decompression and suctioning. These are therapeutic and physiological functions performed directly on the patient's body.
- Device Description: The description details a multi-lumen tube placed in the esophagus and stomach for temperature modulation and gastric access. This is a physical device interacting with the patient's internal environment.
- Lack of IVD Characteristics: There is no mention of the device being used to examine specimens derived from the human body (like blood, urine, tissue, etc.) to provide information for diagnosis, monitoring, or compatibility testing.
IVD devices are used in vitro (outside the body) to analyze samples to gain diagnostic or other medical information. This device operates in vivo (inside the body) for therapeutic and supportive purposes.
N/A
Intended Use / Indications for Use
Model #ECD01-A: The EnsoETM is a thermal regulating device, intended to: · connect to a Gaymar Medi-Therm III Conductive Hyper/Hypothermia System or Stryker Altrix Precision Temperature Management System to control patient temperature, · and provide gastric decompression and suctioning. Model # ECD02-A The EnsoETM is a thermal regulating device, intended to: · connect to a Cincinnati Sub-Zero Blanketrol III Hyper-Hypothermia System to control patient temperature, · and provide gastric decompression and suctioning.
Product codes (comma separated list FDA assigned to the subject device)
PLA
Device Description
The EnsoETM is a multi-lumen silicone tube that is placed in the esophagus in a similar manner to a standard orogastric tube to modulate a patient's temperature, while simultaneously maintaining access to the stomach to allow gastric decompression and drainage, thereby maintaining the functionality of the standard orogastric tube. Modulation and control of patient temperature is achieved by connecting the EnsoETM to an external heat exchanger. Two lumens connect to the external heat exchanger. A third central lumen connects to wall suction and is used for standard gastric decompression. The EnsoETM is made of standard medical-grade silicone. It is a single-use, disposable, non-implantable device with an intended duration of use of 72 hours or less.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
esophagus, stomach
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
A retrospective analysis of real-world human use data was conducted to demonstrate the subject devices are safe and effective for an intended duration of use of 72 hours by analyzing real-world human clinical data from 18 patients. The results of all testing and data analysis demonstrate Subject Device 2 are substantially equivalent to Predicate Device 1 and Predicate Device 2 respectively.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.5910 Esophageal thermal regulation device.
(a)
Identification. An esophageal thermal regulation device is a prescription device used to apply a specified temperature to the endoluminal surface of the esophagus via an external controller. This device may incorporate a mechanism for gastric decompression and suctioning. The device is used to regulate patient temperature.(b)
Classification. Class II (special controls). The special controls for this device are:(1) The patient contacting materials must be demonstrated to be biocompatible.
(2) Non-clinical performance evaluation must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested:
(i) Mechanical integrity testing.
(ii) Testing to determine temperature change rate(s).
(iii) Testing to demonstrate compatibility with the indicated external controller.
(iv) Shelf life testing.
(3) Animal testing must demonstrate that the device does not cause esophageal injury and that body temperature remains within appropriate boundaries under anticipated conditions of use.
(4) Labeling must include the following:
(i) Detailed insertion instructions.
(ii) Warning against attaching the device to unintended connections, such as external controllers for which the device is not indicated, or pressurized air outlets instead of vacuum outlets for those devices, including gastric suction.
(iii) The operating parameters, name, and model number of the indicated external controller.
(iv) The intended duration of use.
0
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo is in blue and includes the letters "FDA" in a square and the words "U.S. FOOD & DRUG ADMINISTRATION".
October 17, 2017
Attune Medical Erik Kulstad President/CEO 3440 S. Dearborn St. #215-South Chicago, Illinois 60616
Re: K172493
Trade/Device Name: EnsoETM Regulation Number: 21 CFR 870.5910 Regulation Name: Esophageal Thermal Regulation Device Regulatory Class: Class II Product Code: PLA Dated: August 16, 2017 Received: August 18, 2017
Dear Erik Kulstad:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
1
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education (DICE) at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevicesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education (DICE) at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely,
Nicole G. Ibrahim -S
for Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K172493
Device Name EnsoETM
Indications for Use (Describe)
Model #ECD01-A:
The EnsoETM is a thermal regulating device, intended to:
· connect to a Gaymar Medi-Therm III Conductive Hyper/Hypothermia System or Stryker Altrix Precision Temperature Management System to control patient temperature,
· and provide gastric decompression and suctioning.
Model # ECD02-A
The EnsoETM is a thermal regulating device, intended to:
· connect to a Cincinnati Sub-Zero Blanketrol III Hyper-Hypothermia System to control patient temperature,
· and provide gastric decompression and suctioning.
| Type of Use (Select one or both, as applicable) |
|---|
| ------------------------------------------------- |
X Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
SECTION 5: 510(k) Summary of Safety and Effectiveness
Submitter / 510(k) Holder
| Company: | Attune Medical |
|---|---|
| Address: | 3440 S. Dearborn St. |
| #215-South | |
| Chicago, IL 60616 | |
| Phone: | +1-312-725-4756 |
| Contact Person: | Erik Kulstad |
| CEO/President | |
| Date Prepared: | August 16, 2017 |
| Device Name & Classification | |
| Trade Name: | EnsoETM |
| Model Number(s): | ECD01-A, ECD02-A |
| Classification Name: | Esophageal Thermal Regulation Device (21 CFR 870.5910) |
| Product Code: | PLA |
| Class: | II |
| Predicate Device |
-
Attune Medical EnsoETM (model #: ECD01-A); K170009
-
Attune Medical EnsoETM (model #: ECD02-A); K152450
Device Description
The EnsoETM is a multi-lumen silicone tube that is placed in the esophagus in a similar manner to a standard orogastric tube to modulate a patient's temperature, while simultaneously maintaining access to the stomach to allow gastric decompression and drainage, thereby maintaining the functionality of the standard orogastric tube. Modulation and control of patient temperature is achieved by connecting the EnsoETM to an external heat exchanger. Two lumens connect to the external heat exchanger. A third central lumen connects to wall suction and is used for standard gastric decompression. The EnsoETM is made of standard medical-grade silicone. It is a single-use, disposable, non-implantable device with an intended duration of use of 72 hours or less.
Indications for Use (Subject Device 1; Model #: ECD01-A)
The EnsoETM is a thermal regulating device, intended to:
- connect to a Gaymar Medi-Therm III Conductive Hyper/Hypothermia System or Stryker Altrix Precision Temperature Management System to control patient temperature,
- provide gastric decompression and suctioning.
4
Indications for Use (Subject Device 2; Model #: ECD02-A)
The EnsoETM is a thermal regulating device, intended to:
- . connect to a Cincinnati Sub-Zero Blanketrol III Hyper-Hypothermia System to control patient temperature, and
- provide gastric decompression and suctioning.
Technological Characteristics
The EnsoETM product family currently consists of two models: the ECD01-A (Predicate Device 1 cleared under K170009) and ECD02-A (Predicate Device 2 cleared under K152450). The purpose of this 510(k) submission is to increase the intended duration of use for the EnsoETM product family from 36 hours to 72 hours. Table 1 describes the differences between the predicate and subject devices. Device characteristics not described in Table 1 are identical for all devices.
| Model # | Coolant Lumen Fittings | Intended Heat Exchanger | Intended
Duration of Use |
|---------------------------------|---------------------------------|--------------------------------------------------------|-----------------------------|
| ECD01-A (Predicate
Device 1) | Clik-Tite connectors | Stryker/Gaymar Medi-Therm III or
Stryker Altrix | 36 hours |
| ECD02-A (Predicate
Device 2) | Colder PLC series
connectors | Cincinnati Sub-Zero Blanketrol II or
Blanketrol III | 36 hours |
| ECD01-A (Subject
Device 1) | Clik-Tite connectors | Stryker/Gaymar Medi-Therm III or
Stryker Altrix | 72 hours |
| ECD02-A (Subject
Device 2) | Colder PLC series
connectors | Cincinnati Sub-Zero Blanketrol II or
Blanketrol III | 72 hours |
Table 1: Differences between EnsoETM models
Subject Device 1 has the identical technological characteristics (including indications for use, patient population, principles of operation, materials, and design) as Predicate Device 1. The only difference is the increase in the intended duration of use from 36 hours to 72 hours.
Subject Device 2 has the technological characteristics (including indications for use, patient population, principles of operation, materials, and design) as Predicate Device 2. The only difference is the increase in the intended duration of use from 36 hours to 72 hours.
Performance Testing
A retrospective analysis of real-world human use data was conducted to demonstrate the subject devices are safe and effective for an intended duration of use of 72 hours by analyzing real-world human clinical data from 18 patients.
Conclusion
The results of all testing and data analysis demonstrate Subject Device 2 are substantially equivalent to Predicate Device 1 and Predicate Device 2 respectively.